Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 57, Issue 4, 2017, Pages 1105-1121

  Tönnies, Eric ^a   Trushina, Eugenia ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer's disease; amyloid ; antioxidants; caloric restriction; exercise; mitochondria; mitohormesis; neurotransmission; oxidative stress; synaptic function; tau protein

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; ASCORBIC ACID; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TAU PROTEIN; THIOCTIC ACID;

ALZHEIMER DISEASE; CALORIC RESTRICTION; EXERCISE; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; VITAMIN SUPPLEMENTATION; ANIMAL; METABOLISM; PHYSIOLOGY; SYNAPSE;

ALZHEIMER DISEASE; ANIMALS; HUMANS; OXIDATIVE STRESS; SYNAPSES;

EID: 85018724016     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-161088     Document Type: Review

References (231)

1. Alzheimer's Disease International, https://www.alz.co. uk/research/WorldAlzheimerReport2015.pdf.
2. Kandimalla R, Thirumala V, Reddy PH (2016) Is Alzheimer's disease a type 3 diabetes? Acritical appraisal. Biochim Biophys Acta. doi: 10.1016/j.bbadis.2016.08.018
3. Wang Y, Brinton RD (2016) Triad of risk for late onset Alzheimer's: Mitochondrial haplotype, APOE genotype and chromosomal sex. Front Aging Neurosci 8, 232.
4. Tramutola A, Lanzillotta C, Perluigi M, Butterfield DA (2016) Oxidative stress, protein modification and Alzheimer disease. Brain Res Bull. doi: 10.1016/j.brainres bull.2016.06.005
5. Selkoe DJ (2008) Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb Clin Neurol 89, 245-260.
6. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
7. Selkoe DJ (2008) Soluble oligomers of the amyloid betaprotein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113.
8. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC (2001) Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125, 489-492.
9. Oddo S, Caccamo A, Shepherd JD, MurphyMP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
10. Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28, 1297-1306.
11. Xu H, Greengard P, Gandy S (1995) Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. J Biol Chem 270, 23243-23245.
12. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT (2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 116, 3339-3346.
13. Mizuguchi M, Ikeda K, Kim SU (1992) Differential distribution of cellular forms of beta-amyloid precursor protein in murine glial cell cultures. Brain Res 584, 219-225.
14. Omtri RS, Davidson MW, Arumugam B, Poduslo JF, Kandimalla KK (2012) Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: Ramifications for the Alzheimer's drug discovery. Mol Pharm 9, 1887-1897.
15. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8, 79-84.
16. Lai AY, McLaurin J (2010) Mechanisms of amyloid-beta peptide uptake by neurons: The role of lipid rafts and lipid raft-associated proteins. Int J Alzheimers Dis 2011, 548380.
17. Andreadis A, Brown WM, Kosik KS (1992) Structure and novel exons of the human tau gene. Biochemistry 31, 10626-10633.
18. Miller EC, Teravskis PJ, Dummer BW, Zhao X, Huganir RL, Liao D (2014) Tau phosphorylation and tau mislocalization mediate soluble Abeta oligomer-induced AMPA glutamate receptor signaling deficits. Eur J Neurosci 39, 1214-1224.
19. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid betaprotein. J Alzheimers Dis 3, 75-80.
20. Jack CR Jr, Holtzman DM (2013) Biomarker modeling of Alzheimer's disease. Neuron 80, 1347-1358.
21. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L (1988) Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38, 1682-1687.
22. Iacono D, Resnick SM, O'Brien R, Zonderman AB, An Y, PletnikovaO, RudowG, Crain B,Troncoso JC (2014) Mild cognitive impairment and asymptomatic Alzheimer disease subjects: Equivalent beta-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol 73, 295-304.
23. Sepulcre J, Schultz AP, Sabuncu M, Gomez-Isla T, Chhatwal J, Becker A, Sperling R, Johnson KA (2016) In vivo tau, amyloid, and gray matter profiles in the aging brain. J Neurosci 36, 7364-7374.
24. Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 139, 1551-1567.
25. Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM (2016) Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy. JAMANeurol 73, 1070-1077.
26. JackCRJr, Knopman DS, Jagust WJ, ShawLM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
27. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: The challenge of the second century. Sci Transl Med 3, 77sr71.
28. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, HoltzmanDM,Santacruz A, BucklesV, OliverA, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
29. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study. Lancet Neurol 11, 669-678.
30. Herrup K (2015) The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 18, 794-799.
31. Castello MA, Jeppson JD, Soriano S (2014) Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. BMC Neurol 14, 169.
32. Castellani RJ, Smith MA (2011) Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J Pathol 224, 147-152.
33. Swerdlow RH, Burns JM, Khan SM (2014) The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim Biophys Acta 1842, 1219-1231.
34. Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1366, 211-223.
35. Beal MF (2005) Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 26, 585-586.
36. Atamna H, Frey WH, 2nd (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7, 297-310.
37. Baloyannis SJ, Costa V, Michmizos D (2004) Mitochondrial alterations in Alzheimer's disease. Am J Alzheimers Dis Other Demen 19, 89-93.
38. Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58, 495-505.
39. Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 20, 4515-4529.
40. Cardoso SM, Pereira CF, Moreira PI, Arduino DM, Esteves AR, Oliveira CR (2010) Mitochondrial control of autophagic lysosomal pathway in Alzheimer's disease. Exp Neurol 223, 294-298.
41. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR (2004) Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89, 1417-1426.
42. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19, 2040-2041.
43. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS (2010) Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A 107, 18670-18675.
44. Eckert A, Hauptmann S, Scherping I, Rhein V, Muller-Spahn F, Gotz J, Muller WE (2008) Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis 5, 157-159.
45. Leuner K, Schutt T, Kurz C, Eckert SH, Schiller C, Occhipinti A, Mai S, Jendrach M, Eckert GP, Kruse SE, Palmiter RD, Brandt U, Drose S, Wittig I, Willem M, Haass C, Reichert AS, Muller WE (2012) Mitochondrionderived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal 16, 1421-1433.
46. Manczak M, Calkins MJ, ReddyPH(2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: Implications for neuronal damage. Hum Mol Genet 20, 2495-2509.
47. Trushina E, McMurray CT (2007) Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145, 1233-1248.
48. Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J, Siddiqui A, Tamura Y, Sesaki H, Wengenack TM, Dzeja PP, Poduslo JF (2012) Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 7, e32737.
49. Zhu X, Perry G, Smith MA, Wang X (2013) Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 33(Suppl 1), S253-S262.
50. Kandimalla R, Reddy PH (2016) Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. Biochim Biophys Acta 1862, 814-828.
51. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for lateonset Alzheimer's dementia. Proc Natl Acad Sci USA101, 284-289.
52. Jagust WJ, Landau SM (2012) Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 32, 18227-18233.
53. Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147, 180-195.
54. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications. Ann Neurol 57, 695-703.
55. Blass JP (2000) The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann N Y Acad Sci 924, 170-183.
56. Schmitt K, Grimm A, Kazmierczak A, Strosznajder JB, Gotz J, Eckert A (2012) Insights into mitochondrial dysfunction: Aging, amyloid-beta, and tau-A deleterious trio. Antioxid Redox Signal 16, 1456-1466.
57. Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 1415, 136-148.
58. Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, Butterfield DA (2011) Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: Insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis 24, 77-84.
59. Caldwell CC, Yao J, Brinton RD (2015) Targeting the prodromal stage of Alzheimer's disease: Bioenergetic and mitochondrial opportunities. Neurotherapeutics 12, 66-80.
60. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, BrintonRD(2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad SciUS A 106, 14670-14675.
61. Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM (2010) Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis 22, 307-313.
62. Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822, 639-649.
63. Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 8, e63644.
64. Jones DP (2006) Redefining oxidative stress. Antioxid Redox Signal 8, 1865-1879.
65. Hauptmann N, Grimsby J, Shih JC, Cadenas E (1996) The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch Biochem Biophys 335, 295-304.
66. Di Meo S, Reed TT, Venditti P, Victor VM (2016) Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev 2016, 1245049.
67. Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24, 981-990.
68. Holmstrom KM, Finkel T (2014) Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol 15, 411-421.
69. Quinlan CL, Perevoshchikova IV, Hey-Mogensen M, Orr AL, Brand MD (2013) Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. Redox Biol 1, 304-312.
70. Joshi G, Johnson JA (2012) The Nrf2-ARE pathway: A valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 7, 218-229.
71. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47, 89-116.
72. Denzer I, Munch G, Friedland K (2016) Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds. Pharmacol Res 103, 80-94.
73. Patel M (2016) Targeting oxidative stress in central nervous system disorders. Trends Pharmacol Sci 37, 768-778.
74. Bhat AH, Dar KB, Anees S, Zargar MA, Masood A, Sofi MA,GanieSA(2015) Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed Pharmacother 74, 101-110.
75. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66, 75-85.
76. Tanji K, Maruyama A, Odagiri S, Mori F, Itoh K, Kakita A, Takahashi H,WakabayashiK(2013)Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases. J Neuropathol Exp Neurol 72, 18-28.
77. Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, Arvanitakis Z (2006) Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 27, 252-261.
78. Kanninen K, Malm TM, Jyrkkanen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H, Yamamoto M, Yla-Herttuala S, Levonen AL, Koistinaho J (2008) Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci 39, 302-313.
79. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU (2006) Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21, 344-348.
80. Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases:Areview of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7, 65-74.
81. Smith MA, Rudnicka-Nawrot M, Richey PL, Praprotnik D, Mulvihill P, Miller CA, Sayre LM, Perry G (1995) Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 64, 2660-2666.
82. Butterfield DA, Di Domenico F, Barone E (2014) Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochim Biophys Acta 1842, 1693-1706.
83. Kosenko EA, Solomadin IN, Tikhonova LA, Reddy VP, AlievG, KaminskyYG(2014) Pathogenesis of Alzheimer disease: Role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism. CNS Neurol Disord Drug Targets 13, 112-119.
84. Castellani RJ, Moreira PI, Perry G, Zhu X (2012) The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 38, 133-138.
85. Zhu X, Raina AK, Lee HG, Chao M, Nunomura A, Tabaton M, Petersen RB, Perry G, Smith MA (2003) Oxidative stress and neuronal adaptation in Alzheimer disease: The role of SAPK pathways. Antioxid Redox Signal 5, 571-576.
86. Markesbery WR (1999) The role of oxidative stress in Alzheimer disease. Arch Neurol 56, 1449-1452.
87. Pratico D (2008) Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci 29, 609-615.
88. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller-Thomsen T, Beisiegel U (2000) Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 28, 351-360.
89. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ,Wiggert B, Petersen RB, PerryG(1994) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145, 42-47.
90. Ramassamy C, Krzywkowski P, Averill D, Lussier-Cacan S, Theroux L, Christen Y, Davignon J, Poirier J (2001) Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. Brain Res Mol Brain Res 86, 76-83.
91. Picklo MJ, Montine TJ, Amarnath V, Neely MD (2002) Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 184, 187-197.
92. Bassett CN, Montine TJ (2003) Lipoproteins and lipid peroxidation in Alzheimer's disease. J Nutr Health Aging 7, 24-29.
93. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U (1997) Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 31, 53-64.
94. Lovell MA, Markesbery WR (2007) Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35, 7497-7504.
95. Lovell MA, Markesbery WR (2008) Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis 29, 169-175.
96. Bradley-Whitman MA, Timmons MD, Beckett TL, Murphy MP, Lynn BC, Lovell MA (2014) Nucleic acid oxidation: An early feature of Alzheimer's disease. J Neurochem 128, 294-304.
97. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, Nucciarone B, Siciliano G (2005) Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26, 567-573.
98. Greenough MA, Camakaris J, Bush AI (2013) Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 62, 540-555.
99. Wang P, Wang ZY (2016) Metal ions influx is a double edged sword for the pathogenesis of Alzheimer's disease. Ageing Res Rev. doi: 10.1016/j.arr.2016.10.003
100. Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, Tanzi RE, Rogers JT, Huang X (2006) Metal exposure and Alzheimer's pathogenesis. J Struct Biol 155, 45-51.
101. Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, Stoltenberg M, Ravid R (1997) Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: A proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 76, 53-59.
102. Friedlich AL, Lee JY, van Groen T, Cherny RA, Volitakis I, Cole TB, Palmiter RD, Koh JY, Bush AI (2004) Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J Neurosci 24, 3453-3459.
103. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A 99, 7705-7710.
104. Lee JY, Mook-Jung I, Koh JY (1999) Histochemically reactive zinc in plaques of the Swedish mutant betaamyloid precursor protein transgenic mice. J Neurosci 19, RC10.
105. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52.
106. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J (2006) Synchrotron-based infrared and Xray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J Struct Biol 155, 30-37.
107. Stoltenberg M, Bush AI, Bach G, Smidt K, Larsen A, Rungby J, Lund S, Doering P, Danscher G (2007) Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 150, 357-369.
108. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ (2000) Histochemicallyreactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 852, 274-278.
109. Boom A, Pochet R, Authelet M, Pradier L, Borghgraef P, Van Leuven F, Heizmann CW, Brion JP (2004) Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in PS1/APP transgenic mice models. Biochim Biophys Acta 1742, 161-168.
110. Heizmann CW, Cox JA (1998) New perspectives on S100 proteins:Amulti-functional Ca(2+)-, Zn(2+)-and Cu(2+)-binding protein family. Biometals 11, 383-397.
111. Barnham KJ, Bush AI (2014) Biological metals and metaltargeting compounds in major neurodegenerative diseases. Chem Soc Rev 43, 6727-6749.
112. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 96, 3922-3927.
113. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265, 1464-1467.
114. Tougu V, Karafin A, Palumaa P (2008) Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide. J Neurochem 104, 1249-1259.
115. MantyhPW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE (1993) Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 61, 1171-1174.
116. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals. J Neurochem 74, 270-279.
117. Boom A, Authelet M, Dedecker R, Frederick C, Van Heurck R, Daubie V, Leroy K, Pochet R, Brion JP (2009) Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells. Biochim Biophys Acta 1793, 1058-1067.
118. Stohs SJ, Bagchi D (1995) Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 18, 321-336.
119. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609-7616.
120. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA,Wilkins S, Deleva K, Lynch T,KokG, RitchieCW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
121. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
122. Opazo C, Barria MI, Ruiz FH, InestrosaNC(2003) Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. Biometals 16, 91-98.
123. Cristovao JS, Santos R, Gomes CM (2016) Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer's Disease. Oxid Med Cell Longev 2016, 9812178.
124. Nakajima K, Kohsaka S (2001) Microglia: Activation and their significance in the central nervous system. J Biochem 130, 169-175.
125. Gibson GE, Karuppagounder SS, Shi Q (2008) Oxidantinduced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer's disease. Ann N Y Acad Sci 1147, 221-232.
126. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of Abeta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
127. MattsonMP, Cutler RG, JoDG(2005) Alzheimer peptides perturb lipid-regulating enzymes. Nat Cell Biol 7, 1045-1047.
128. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY(2004) Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinaseceramide pathway. J Cell Biol 164, 123-131.
129. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA,De Strooper B, Muller U, Shen J, Hartmann T (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 7, 1118-1123.
130. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 101, 2070-2075.
131. Chalfant CE, Kishikawa K, Mumby MC, Kamibayashi C, Bielawska A, Hannun YA (1999) Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 274, 20313-20317.
132. Haughey NJ, Bandaru VV, Bae M, Mattson MP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 1801, 878-886.
133. Blass JP, Baker AC, Ko L, Black RS (1990) Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol 47, 864-869.
134. Szabados T, Dul C, Majtenyi K, Hargitai J, Penzes Z, Urbanics R (2004) A chronic Alzheimer's model evoked by mitochondrial poison sodium azide for pharmacological investigations. Behav Brain Res 154, 31-40.
135. Ichimura H, Parthasarathi K, Quadri S, Issekutz AC, Bhattacharya J (2003) Mechano-oxidative coupling by mitochondria induces proinflammatory responses in lung venular capillaries. J Clin Invest 111, 691-699.
136. Colell A, Fernandez A, Fernandez-Checa JC (2009) Mitochondria, cholesterol and amyloid beta peptide: A dangerous trio in Alzheimer disease. J Bioenerg Biomembr 41, 417-423.
137. Rosales-Corral SA, Lopez-Armas G, Cruz-Ramos J, Melnikov VG, Tan DX, Manchester LC, Munoz R, Reiter RJ (2012) Alterations in lipid levels of mitochondrial membranes induced by amyloid-beta: A protective role of melatonin. Int J Alzheimers Dis 2012, 459806.
138. Mondragon-Rodriguez S, Perry G, Zhu X, Moreira PI, Acevedo-Aquino MC, Williams S (2013) Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: Implications for Alzheimer's disease. Oxid Med Cell Longev 2013, 940603.
139. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME, Mintun MA (2010) Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci U S A 107, 17763-17767.
140. Onyango IG, Ahn JY, Tuttle JB, Bennett JP Jr, Swerdlow RH (2010) Nerve growth factor attenuates oxidant-induced beta-amyloid neurotoxicity in sporadic Alzheimer's disease cybrids. J Neurochem 114, 1605-1618.
141. Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker WD Jr, Bennett JP Jr (2000) Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 48, 148-155.
142. Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, Trabucchi M, Govoni S (1997) Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett 231, 113-117.
143. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269, 13623-13628.
144. Webster MT, Pearce BR, Bowen DM, Francis PT (1998) The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm (Vienna) 105, 839-853.
145. Henriques AG, Domingues SC, Fardilha M, da Cruz e Silva EF, da Cruz e Silva OA (2005) Sodium azide and 2-deoxy-D-glucose-induced cellular stress affects phosphorylation-dependent AbetaPP processing. J Alzheimers Dis 7, 201-212; discussion 255-262.
146. Szule JA, Jung JH, McMahan UJ (2015) The structure and function of 'active zone material' at synapses. Philos Trans R Soc Lond B Biol Sci 370, 1672.
147. Malenka RC, Bear MF (2004) LTP and LTD: An embarrassment of riches. Neuron 44, 5-21.
148. Neves G, Cooke SF, Bliss TV (2008) Synaptic plasticity, memory and the hippocampus:Aneural network approach to causality. Nat Rev Neurosci 9, 65-75.
149. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7, 278-294.
150. Jang SS, Chung HJ (2016) Emerging link between Alzheimer's disease and homeostatic synaptic plasticity. Neural Plas 2016, 7969272.
151. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464.
152. Hamos JE, DeGennaro LJ, DrachmanDA(1989) Synaptic loss in Alzheimer's disease and other dementias. Neurology 39, 355-361.
153. Robinson JL, Molina-Porcel L, Corrada MM, Raible K, Lee EB, Lee VM, Kawas CH, Trojanowski JQ (2014) Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. Brain 137, 2578-2587.
154. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
155. Serrano-Pozo A, FroschMP,Masliah E, HymanBT(2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189.
156. Cooper LN, Bear MF (2012) The BCM theory of synapse modification at 30: Interaction of theory with experiment. Nat Rev Neurosci 13, 798-810.
157. Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82, 756-771.
158. Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C, TyagiN(2016) Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer's disease: Understanding the therapeutics strategies. Mol Neurobiol 53, 648-661.
159. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14, 45-53.
160. Newcomer JW, Farber NB, Olney JW (2000) NMDA receptor function, memory, and brain aging. Dialogues Clin Neurosci 2, 219-232.
161. Frankland PW, Bontempi B (2005) The organization of recent and remote memories. Nat Rev Neurosci 6, 119-130.
162. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058.
163. Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 31, 454-463.
164. Parsons MP, Raymond LA (2014) Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82, 279-293.
165. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov 5, 160-170.
166. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843.
167. Li Y, Sun H, Chen Z, Xu H, Bu G, Zheng H (2016) Implications of GABAergic neurotransmission in Alzheimer's disease. Front Aging Neurosci 8, 31.
168. Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221, 555-563.
169. Campos C, Rocha NB, Vieira RT, Rocha SA, Telles-Correia D, Paes F, Yuan T, Nardi AE, Arias-Carrion O, Machado S, Caixeta L (2016) Treatment of cognitive deficits in Alzheimer's disease: A psychopharmacological review. Psychiatr Danub 28, 2-12.
170. Ellis B, Hye A, Snowden SG (2015) Metabolic modifications in human biofluids suggest the involvement of sphingolipid, antioxidant, and glutamate metabolism in Alzheimer's disease pathogenesis. J Alzheimers Dis 46, 313-327.
171. Trushina E, Mielke MM (2013) Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta 1842, 1232-1239.
172. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-Daspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590-11601.
173. Rai S, Kamat PK, Nath C, Shukla R (2013) A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J Neuroimmunol 254, 1-9.
174. Kamat PK, Rai S, Swarnkar S, Shukla R, Ali S, Najmi AK, Nath C (2013) Okadaic acid-induced Tau phosphorylation in rat brain: Role of NMDA receptor. Neuroscience 238, 97-113.
175. Morris G, Walder K, Puri BK, Berk M, Maes M (2016) The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: New drug targets in neuroimmune disorders. Mol Neurobiol 53, 4638-4658.
176. Han X (2010) Multi-dimensional mass spectrometrybased shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim Biophys Acta 1801, 774-783.
177. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R (2011) Metabolomics in early Alzheimer's disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6, e21643.
178. Schneider LS, SanoM(2009) Current Alzheimer's disease clinical trials: Methods and placebo outcomes. Alzheimers Dement 5, 388-397.
179. Cummings J, Aisen PS, DuBois B, Frolich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P (2016) Drug development in Alzheimer's disease: The path to 2025. Alzheimers Res Ther 8, 39.
180. Padurariu M, Ciobica A, Lefter R, Serban IL, Stefanescu C, Chirita R (2013) The oxidative stress hypothesis in Alzheimer's disease. Psychiatr Danub 25, 401-409.
181. Sancheti H, Kanamori K, Patil I, Diaz Brinton R, Ross BD, Cadenas E (2014) Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: A 13C NMR study. J Cereb Blood Flow Metab 34, 288-296.
182. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RWJr (2007) Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 28, 213-225.
183. Rajasekar N, Dwivedi S, Tota SK, Kamat PK, Hanif K, Nath C, Shukla R (2013) Neuroprotective effect of curcumin on okadaic acid induced memory impairment in mice. Eur J Pharmacol 715, 381-394.
184. Zhou X, Li Y, Shi X, Ma C (2016) An overview on therapeutics attenuating amyloid beta level in Alzheimer's disease:Targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res 8, 246-269.
185. Kang JH, Cook N, Manson J, Buring JE, Grodstein F (2006) A randomized trial of Vitamin E supplementation and cognitive function in women. Arch Intern Med 166, 2462-2468.
186. Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, Grodstein F (2009) Vitamin E, Vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. Circulation 119, 2772-2780.
187. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-2388.
188. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222.
189. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL,Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL,Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of Vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 311, 33-44.
190. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005) Meta-analysis: Highdosage Vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142, 37-46.
191. Arlt S, Muller-Thomsen T, Beisiegel U, Kontush A (2012) Effect of one-year Vitamin C-and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. Neurochem Res 37, 2706-2714.
192. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P, Alzheimer's Disease Cooperative Study (2012) Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69, 836-841.
193. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, BadmaevV, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM (2012) Oral curcumin for Alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4, 43.
194. Wojtunik-Kulesza KA, Oniszczuk A, Oniszczuk T, Waksmundzka-Hajnos M (2016) The influence of common free radicals and antioxidants on development of Alzheimer's Disease. Biomed Pharmacother 78, 39-49.
195. Mecocci P, Polidori MC (2012) Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 1822, 631-638.
196. Tolonen M, Halme M, Sarna S (1985) Vitamin E and selenium supplementation in geriatric patients: A doubleblind preliminary clinical trial. Biol Trace Elem Res 7, 161-168.
197. Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, Dennis BC, Mathews M, Klein EA, Crowley JJ, Investigators SELECT (2013) A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: The PREADViSE Trial. J Nutr Health Aging 17, 72-75.
198. Dias KS,Viegas C, Jr (2014) Multi-target directed drugs:A modern approach for design of newdrugs for the treatment of Alzheimer's disease. Curr Neuropharmacol 12, 239-255.
199. Remington R, Bechtel C, Larsen D, Samar A, Page R, Morrell C, Shea TB (2016) Maintenance of cognitive performance and mood for individuals with Alzheimer's disease following consumption of a nutraceutical formulation: A one-year, open-label study. J Alzheimers Dis 51, 991-995.
200. Chan A, Remington R, Kotyla E, Lepore A, Zemianek J, Shea TB (2010) A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. J Nutr Health Aging 14, 224-230.
201. Banerjee P, Maity S, Das T, Mazumder S (2011)Adoubleblind randomized placebo-controlled clinical study to evaluate the efficacy and safety of a polyherbal formulation in geriatric age group: A phase IV clinical report. J Ethnopharmacol 134, 429-433.
202. Meng TC, Fukada T, Tonks NK (2002) Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9, 387-399.
203. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG (2004) Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101, 16419-16424.
204. Edgar RS, Green EW, Zhao Y, van Ooijen G, Olmedo M, Qin X, Xu Y, Pan M, Valekunja UK, Feeney KA, Maywood ES, Hastings MH, Baliga NS, Merrow M, Millar AJ, Johnson CH, Kyriacou CP, O'Neill JS, Reddy AB (2012) Peroxiredoxins are conserved markers of circadian rhythms. Nature 485, 459-464.
205. Ha EM, Oh CT, Bae YS, Lee WJ (2005) A direct role for dual oxidase in Drosophila gut immunity. Science 310, 847-850.
206. Mathers J, Fraser JA, McMahon M, Saunders RD, Hayes JD, McLellan LI (2004) Antioxidant and cytoprotective responses to redox stress. Biochem Soc Symp, 157-176.
207. Mattson MP (2008) Hormesis defined. Ageing Res Rev 7, 1-7.
208. RistowM(2014) Unraveling the truth about antioxidants: Mitohormesis explains ROS-induced health benefits. Nat Med 20, 709-711.
209. Schmeisser S, Priebe S, Groth M, Monajembashi S, Hemmerich P, Guthke R, Platzer M, RistowM(2013) Neuronal ROS signaling rather than AMPK/sirtuin-mediated energy sensing links dietary restriction to lifespan extension. Mol Metab 2, 92-102.
210. DrogeW(2002) Free radicals in the physiological control of cell function. Physiol Rev 82, 47-95.
211. Kumar A, Singh A (2015) A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions. Front Pharmaco 6, 206.
212. Feniouk BA, SkulachevVP (2016) Cellular and molecular mechanisms of action of mitochondria-targeted antioxidants. Curr Aging Sci 9, doi: 10.2174-1874609809666160 921113706
213. Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, Ebersberger I, Nakashima T, Sarao R, Neely G, Esterbauer H, Kozlov A, Kahn CR, Kroemer G, Rustin P, Burcelin R, Penninger JM (2007) Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 131, 476-491.
214. Wredenberg A, Freyer C, Sandstrom ME, Katz A,Wibom R, Westerblad H, Larsson NG (2006) Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance. Biochem Biophys Res Commun 350, 202-207.
215. Vernochet C, Mourier A, Bezy O, Macotela Y, Boucher J, Rardin MJ, An D, Lee KY, Ilkayeva OR, Zingaretti CM, Emanuelli B, Smyth G, Cinti S, Newgard CB, GibsonBW, Larsson NG, Kahn CR (2012) Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab 16, 765-776.
216. Quintens R, Singh S, Lemaire K, De Bock K, Granvik M, Schraenen A, Vroegrijk IO, Costa V, Van Noten P, Lambrechts D, Lehnert S, Van Lommel L, Thorrez L, De Faudeur G, Romijn JA, Shelton JM, Scorrano L, Lijnen HR, Voshol PJ, Carmeliet P, Mammen PP, Schuit F (2013) Mice deficient in the respiratory chain gene Cox6a2 are protected against high-fat diet-induced obesity and insulin resistance. PLoS One 8, e56719.
217. Raule N, Sevini F, Li S, Barbieri A, Tallaro F, Lomartire L, Vianello D, Montesanto A, Moilanen JS, Bezrukov V, Blanche H, Hervonen A, Christensen K, Deiana L, Gonos ES, Kirkwood TB, Kristensen P, Leon A, Pelicci PG, Poulain M, Rea IM, Remacle J, Robine JM, Schreiber S, Sikora E, Eline Slagboom P, Spazzafumo L, Antonietta Stazi M, Toussaint O, Vaupel JW, Rose G, Majamaa K, Perola M, Johnson TE, Bolund L, Yang H, Passarino G, Franceschi C (2014) The co-occurrence of mtDNA mutations on different oxidative phosphorylation subunits, not detected by haplogroup analysis, affects human longevity and is population specific. Aging Cell 13, 401-407.
218. Copeland JM, Cho J, Lo T Jr, Hur JH, Bahadorani S, Arabyan T, Rabie J, Soh J, Walker DW (2009) Extension of Drosophila life span by RNAi of the mitochondrial respiratory chain. Curr Biol 19, 1591-1598.
219. Lee SS, Lee RY, Fraser AG, Kamath RS, Ahringer J, Ruvkun G (2003) A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity. Nat Genet 33, 40-48.
220. Liu X, Jiang N, Hughes B, Bigras E, Shoubridge E, Hekimi S (2005) Evolutionary conservation of the clk-1-dependent mechanism of longevity: Loss of mclk1 increases cellular fitness and lifespan in mice. Genes Dev 19, 2424-2434.
221. Zhang L, Zhang S, Maezawa I, Trushin S, Minhas P, Pinto M, Jin LW, Prasain K, Nguyen TD,YamazakiY, Kanekiyo T,BuG, Gateno B, ChangKO, NathKA,Nemutlu E, Dzeja P, Pang YP, Hua DH, Trushina E (2015) Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's disease. E Bio Medicine 2, 294-305.
222. Baumgart M, Priebe S, Groth M, Hartmann N, Menzel U, Pandolfini L, Koch P, Felder M, Ristow M, Englert C, Guthke R, Platzer M, Cellerino A (2016) Longitudinal RNA-Seq analysis of vertebrate aging identifies mitochondrial complex i as a small-molecule-sensitive modifier of lifespan. Cell Syst 2, 122-132.
223. Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G (2016) Therapies for prevention and treatment of Alzheimer's disease. Biomed Res Int 2016, 2589276.
224. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement 11, 718-726.
225. Bertram S, Brixius K, Brinkmann C (2016) Exercise for the diabetic brain: How physical training may help prevent dementia and Alzheimer's disease in T2DM patients. Endocrine 53, 350-363.
226. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Cholerton BA, Plymate SR, Fishel MA, Watson GS, Duncan GE, Mehta PD, Craft S (2010) Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis 22, 569-579.
227. Merry TL, Ristow M (2016) Mitohormesis in exercise training. Free Radic Biol Med 98, 123-130.
228. Ntsapi C, Loos B (2016) Caloric restriction and the precision-control of autophagy: A strategy for delaying neurodegenerative disease progression. Exp Gerontol 83, 97-111.
229. Van Cauwenberghe C, Vandendriessche C, Libert C, Vandenbroucke RE (2016) Caloric restriction: Beneficial effects on brain aging and Alzheimer's disease. Mamm Genome 27, 300-319.
230. Hanson AJ, Bayer JL, Baker LD, Cholerton B, VanFossen B, Trittschuh E, Rissman RA, Donohue MC, Moghadam SH, Plymate SR, Craft S (2015) Differential effects of meal challenges on cognition, metabolism, and biomarkers for apolipoprotein E β4 carriers and adults with mild cognitive impairment. J Alzheimers Dis 48, 205-218.
231. Zhang L, Trushin S, Christensen TA, Bachmeier BV, Gateno B, Schroeder A, Yao J, Itoh K, Sesaki H, Poon WW, Gylys KH, Patterson ER, Parisi JE, Diaz Brinton R, Salisbury JL, Trushina E (2016) Altered brain energetics induces mitochondrial fission arrest in Alzheimer's Disease. Sci Rep 6, 18725.